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Abstract
The functional impact of modifications of cellular RNAs, 
including mRNAs, miRNAs and lncRNAs, is a field of 
intense study. The role of such modifications in cancer 
has started to be elucidated. Diverse and sometimes 
opposite effects of RNA modifications have been 
reported. Some RNA modifications promote, while ot­
hers decrease the growth and invasiveness of cancer. 
The present manuscript reviews the current knowledge 
on the potential impacts of N6­Methyladenosine, Pse­
udouridine, Inosine, 2’O­methylation or methylcytidine 
in cancer’s RNA. It also highlights the remaining qu­
estions and provides hints on research avenues and 
potential therapeutic applications, whereby modulating 
dynamic RNA modifications may be a new method to 
treat cancer.
Key words: RNA modifications; N6­methyladenosine; 
5­methylcytidine; 2’O­methylation or methylcytidine; 
Pseudouridine; Inosine
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Core tip: The present manuscript reviews the current 
knowledge on RNA modifications in cancer. The potential 
impacts of N6­Methyladenosine, Pseudouridine, Inosine, 
2’O­methylation or methylcytidine in cancer’s RNA is 
presented and discussed. The review also highlights 
the remaining questions and provides hints on research 
avenues and potential therapeutic applications, whereby 
modulating dynamic RNA modifications may be a new 
method to treat cancer.
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posttrancriptionally in cellular RNAs during their mat­
uration. These modifications are made on canonical A, 
C, G, and U residues, and their formation is catalyzed by 
numerous specific enzymes or RNA-protein complexes 
(RNPs). Ribonucleotide residues can bear single or mu­
ltiple modifications on the purine/pyrimidine ring and/or 
ribose. To date, over one hundred RNA modifications 
have been identified and listed in dedicated databases 
(http://mods.rna.albany.edu/; http://modomics.genesilico.
pl)[1,2]. These naturally occurring modified nucleosides 
play various structural and functional roles in different 
types of RNAs: Transfer RNAs (tRNAs), ribosomal 
RNAs (rRNAs), messenger RNAs (mRNAs), small nu-
clear RNAs (snRNAs), microRNAs (miRNAs) and long 
non­coding RNAs (lncRNAs). The most widespread 
RNA modifications are base or ribose methylations, 
deamination of adenosine to inosine and isomerization 
of uridine into pseudouridine. Over the past decades 
these modifications have been studied in the context 
of malignancies. Frequently, a modification is found to 
have pro­cancer or anti­cancer effects depending on the 
type of RNA, the location of the modification and, most 
importantly, the cell type and context (e.g., hypoxia). 
This review presents the current knowledge on the po­
tential link between RNA modifications and cancer by 
systematically addressing the “pro-cancer”, “anti-cancer” 
and mixed effects of RNA modifications. Since such a 
relationship has been reported for only some abundant 
modifications and for modifications for which a detection 
method is available [N6-Methyladenosine (m6A), 
5-Methylcytidine (m5C), 2’O-mN, Ψ and I], the present 
review will focus on these modifications (Figure 1).
M6A IN CANCER RNA
Serendipitously discovered during the characterization of 
the mRNA 5’ cap, methylation of the exocyclic nitrogen 
of adenosine, named m6A, is by far the most abundant 
mRNA modification, occurring on an average of three 
sites per mRNA[3-5]. Recent technological advances have 
facilitated m6A profiling across eukaryotes, including 
humans, mice[6], yeasts[7], and plants[8,9], indicating that 
m6A is a conserved but dynamic modification. m6A 
has also been identified in rRNA[10], tRNA[11], snRNA[12], 
miRNA[13] and lncRNA[14].
M6A patterns are attributed to the consensus RR­
ACH sequence (A is methylated; R = A or G; H = A, C, 
or U; and the first nucleotide next to m6A from the 5’ 
end most frequently is G), with preferential distribution 
near mRNA stop codons and 3’ untranslated regions 
(UTRs) and within long internal exons. Additionally, the 
m6A sites are conserved between human and mouse 
embryonic stem cells (ESCs) and somatic cells. However, 
distinct m6A patterns can also be detected among 
different species or cells at different developmental sta­
ges[4,7,15,16]. Some m6A signatures are tissue specific[4], 
and are altered in response to different stimuli[17], po-
inting to the potential role of m6A in regulating diverse 
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cellular processes. m6A dynamics are assigned to the 
complex m6A enzymatic machineries, comprising m6A 
“writers”, “readers” and “erasers”. Although a plethora 
of studies suggest crucial and versatile roles of m6A 
and its machineries, its roles in cancer that have re-
cently emerged are contradictory and require further 
investigation. 
High m6A levels in cancers
“Writers” is a term given to enzymes that are part of 
the methyltransferase complex that introduces m6A. 
Components of this complex are methyltransferase-like 
3 (METTL3)[18], METTL14[19], Wilms tumor 1-associated 
protein (WTAP)[20] and KIAA1429[21]. 
METTL3 protein levels were found to be elevated 
in lung adenocarcinoma cell lines compared to healthy 
tissue[22]. Depletion of METTL3 was shown to result in 
the inhibition of cancer cell growth, decreased invasive 
ability of cancer cells and increased cell apoptosis in the 
same study. Additionally, METTL3 was shown to function 
as an m6A­binding protein (“reader”) in a specific 
subset of m6A-modified mRNAs, where it recruits eIF3 
during translation initiation and therefore promotes 
translation. Expression of several oncogenes, including 
the mRNA of epidermal growth factor receptor (EGFR) 
and the Hippo pathway effector transcriptional co­
activator with the PDZ-binding motif (TAZ) protein, was 
found to be promoted upon METTL3 recognition[22].
Similarly, in acute myeloid leukemia (AML), mRNA 
levels of METTL3 and METTL14 are significantly higher 
than in most cancers[23]. METTL3 depletion in MOLM13 
caused differentiation and increased apoptosis, sug-
gesting that high m6A levels may play a role in sustai­
ning undifferentiated leukemic cells in AML[23] (Table 1).
Low m6A levels in cancers
Two m6A “erasers” have been described: Demethylases 
fat mass and obesity­associated protein (FTO) and alkB 
homolog 5 (ALKBH5)[24,25]. 
Single nucleotide polymorphisms within FTO known 
to be involved in the development of obesity in genome­
wide association studies have been associated with the 
risk of developing diverse cancer types: Lung cancer, 
kidney cancer, high-grade prostate cancer, endometrial 
cancer, pancreatic cancer, pancreatic cancer in patients 
with type 2 diabetes, and breast cancer[26-33]. All these 
cancer types share a single SNP (rsrs9939609): The 
obesity-associated SNP in intron 1 of the FTO gene. This 
SNP was shown to increase primary transcript levels of 
the FTO gene, suggesting a gain-of-function mutation in 
cancers associated with this SNP[34]. 
In human epidermal growth factor receptor type 
2 (HER2)-overexpressing subtypes of breast cancer, 
FTO is highly expressed in comparison to other breast 
cancer subtypes[35]. Contrary to the studies of high 
m6A levels in AML discussed in the previous chapter, 
low m6A levels have also been reported in AML sub­
types. FTO expression can be upregulated by certain 
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oncogenic proteins (e.g., mixed lineage leukemia 
(MLL)-fusion proteins, promyelocytic leukemia/retinoic 
acid receptor alpha (PML-RARA), fms-related tyrosine 
kinase 3-internal tandem duplication (FLT3-ITD), 
and nucleophosmin 1 (NPM1) mutant), and dataset 
analysis of human AML confirmed that FTO was 
expressed at significantly high levels in t(11q23)/MLL-
rearranged, t(15;17)/PML-RARA, FLT3-ITD, and/or 
NPM1­mutated AMLs[36]. Overexpression of FTO reduces 
m6A levels in ankyrin repeat and SOCS box containing 
2 (ASB2) and retinoic acid receptor alpha (RARA) 
mRNA transcripts. It has been shown that the loss of 
m6A markings reduces mRNA stability, resulting in 
the partial repression of ASB2 and RARA expression 
in AML cells. In four different AML cohorts, ASB2 and 
RARA exhibit a significant inverse correlation with FTO 
expression. ASB2 and RARA are upregulated during 
normal hematopoiesis and are important regulators of 
all­trans­retinoic acid (ATRA)­induced differentiation 
of leukemia cells. Through regulating the expression 
of such targets, FTO inhibits ATRA-induced AML cell 
differentiation. Both gain­ and loss­of­function studies of 
FTO in leukemic cell models showed an oncogenic role of 
FTO in these AML subtypes[36]. However, recent studies 
have suggested that FTO acts as a demethylase of N6-2’
O-dimethyladenosine in mRNA 5’ caps, having only 
minor effects on m6A[37]. Thus, the role of FTO in AML 
might be independent of m6A.
Recently, both FTO and ALKBH5 have been found 
to play similar roles in glioblastoma stem cells (GSCs) 
and their tumorigenesis[38]. These studies shed light on 
their crucial roles in the regulation of mRNA m6A levels 
for maintaining GSC growth, self-renewal, and tumor 
development. Enhanced growth and self­renewal of 
GSCs in vitro were detected upon the depletion of 
METTL3 or METTL14, resulting in reduced mRNA m6A 
levels, and promoted the ability of GSCs to form brain 
tumors in vivo. Accordingly, treatment with the FTO 
inhibitor MA2, the ethyl ester form of meclofenamic 
acid, increased mRNA m6A levels and suppressed 
GSC growth in vitro and GSC-initiated tumorigenesis, 
ultimately prolonging the survival of GSC-engrafted 
mice. 
In a similar study, the authors checked the expr-
ession levels of m6A regulators in available datasets for 
glioblastoma multiforme (GBM) and discovered elevated 
expression of m6A demethylase ALKBH5 that correlated 
with poor clinical outcomes for GBM patients[39]. Stable 
knockdowns in cultured human GSCs showed that 
the loss of ALKBH5 decreases GSC proliferation and 
reduces the expression of the stemness markers Nestin, 
Sox2, Nanog, and Oct4, which are normally expressed 
in GSCs. In rescue experiments, wild-type, but not 
catalytically inactive, ALKBH5 recover the phenotype, 
suggesting that it plays a role in stemness maintenance 
and that the proliferation of GSCs is solely based on 
demethylation activity. Moreover, these authors ex-
amined the expression of transcription factor FOXM1 
(forkhead box m1), which is known to play a pivotal 
role in regulating GSC proliferation, self-renewal, and 
tumorigenicity, and found that it depends on ALKBH5 
demethylating activity. All these findings were based on 
m6A hyper erasing, which opens new possibilities for 
promising targeted treatments in glioblastoma (Table 1).
It has been reported that the hypoxia-inducible 
factors (HIFs) HIF-1α and HIF-2α activate ALKBH5 
gene transcription under hypoxic conditions in breast 
cancer cells, thus inducing m6A demethylation. This 
demethylation was shown to stabilize NANOG mRNA 
and promote the breast cancer stem cell (BCSC) 
Table 1  Relative amount of modification (directly quantified or extrapolated from the expression level of writers/erasers)
RNA modifications High in cancer Low in cancer
m6A Lung adenocarcinoma[22], AML[23] HER2 overexpressing subtypes breast cancer[35], t(11q23)/MLL-
rearranged, t(15;17)/PML-RARA, FLT3-ITD, and/or NPM1-
mutated AMLs (ASB2 and RARA)[36], GBM (FOXM1)[39], breast 
cancer (NANOG)[40]
2’O-methylation Breast cancer [51,67], primary and metastatic prostate cancers[58], 
squamous cell cervical carcinoma[57]
Ψ Leukemia, lymphoma, multiple myeloma[84-86]
Inosine BLCA, BRCA, COAD, HNSC, LUAD, THCA[87,88], NSCLC 
(NEIL1[94], AZIN1[103], miR-381[94]), SCLC (AZIN1)[87], HCC  
(AZIN1[101], FLNB[90]), GC[91], ESCC (FLNB)[92], cervical 
cancer[89], CRC (RHOQ)[109], AML (PTPN6)[114]
KIRP, KICH[87,88], Breast cancer (Gabra3)[118], Gastric cancer 
(PODXL)[91], Glioblastoma (GluR-B)[119], onco miR-21, miR-221, 
miR-222[128], ESCC (IGFBP7)[120], Glioma (miR-376a*)[129], 
Melanoma[130] (miR-455-5p)[132]
5mC Circulating tumor cells in lung cancer[137]
In brackets are the names of genes that have been analyzed. AZIN1: Antizyme inhibitor 1; RHOQ: Ras homolog family member Q; PODXL: Podocalyxin-
like; IGFBP7: Insulin-like growth factor-binding protein 7; PTPN6: Protein tyrosine phosphatase non-receptor type 6; NEIL1: NEI-like protein 1; GluR-B: 
Glutamate R-B; Gabra3: Alpha-3 subunit of gamma-aminobutyric acid type A; FlnB: Filamin B; ASB2: Ankyrin repeat and SOCS box containing 2; RARA: 
Retinoic acid receptor alpha; FOXM1: Forkhead box protein M1; GBM: Glioblastoma multiforme; HER2: Human epidermal growth factor receptor type 
2; MLL: Mixed lineage leukemia; PML/RARA: Promyelocytic leukemia/retinoic acid receptor alpha; FLT3-ITD: Fms-related tyrosine kinase 3–internal 
tandem duplication; NPM1: Nucleophosmin 1; NSCLC: Non-small cell lung cancer; HCC: Hepatocellular carcinoma; ESCC: Esophageal cell carcinoma;  GC: 
Gastric cancer; CRC: Colorectal cancer; AML: Acute myeloid leukemia; SCLC: Small cell lung cancer; BLCA: Bladder urothelial carcinoma; BRCA: Breast 
invasive carcinoma; COAD: Colon adenocarcinoma; HNSC: Head and neck squamous cell carcinoma; LUAD: Lung adenocarcinoma; THCA: Thyroid 
carcinoma; KICH: Kidney chromophobe; KIRP: Kidney renal papillary cell carcinoma.
June 10, 2018|Volume 9|Issue 3|
Tusup M et al . Epitranscriptomics of cancer
45WJCO|www.wjgnet.com
phenotype. Depletion of ALKBH5 in hypoxic breast 
cancer cells was identified as an effective strategy to 
decrease NANOG expression and limit the presence of 
BCSCs in vivo[40] (Table 1). 
Mixed role of m6A in cancer
The primary microRNA (pri­miRNA) junction region 
between the hairpin stem and the flanking single­
stranded RNA was found to be abundant in m6A co­
nsensus motifs. The recognition of the junction regions 
is mediated by Dicer, followed by the recruitment of the 
ribonuclease Drosha (the microprocessor complex), 
which cleaves the RNA duplex to yield the premiRNA 
product. Depletion of HNRNPA2B1 (a nuclear “reader”) 
or METTL3 knockdown in HEK293 and MDA-MB-231 
cells resulted in a significant reduction in the expression 
levels of the mature forms of a number of m6A­marked 
miRNAs. The tumor­suppressor miRNA let­7 was si­
gnificantly reduced upon the depletion of METTL3 po­
ssibly due to diminished Dicer binding to pri-miRNAs, 
thus preventing the formation of mature miRNAs. 
However, these METTL3-depletion experiments also 
showed a decrease in the expression of onco-miRNAs, 
such as miR-221 and miR-222[13,41]. Taken together, the 
presence of m6A affects diverse pri­miRNA and mature 
miRNA subpopulations, but its relevance in the context 
of cancer still needs to be investigated.
2’O-METHYLATION IN CANCER RNA
Methylation of the 2’-hydroxyl group of ribose is one 
of the predominant internal modifications of rRNA and 
snRNA[10,42]. This modification is also found in tRNA and 
mRNA, mostly at the first and second nucleotides in 
Cap1 and Cap2 structures, respectively.
Introducing 2’O-methylation on ribose is mediated 
by complexes of guide RNA and proteins named small 
nucleolar ribonucleoprotein (snoRNP) complexes or by 
methyltransferases: Human cap1 and 2, 2’-O­ribose 
methyltransferase, hMTr1 and hMTr2[43-45]. snoRNP 
complexes consist of Fibrillarin (the catalytic component 
in humans, also known as Nop1p in yeast), Nol5a 
(Nop56p), Nop58 and Snu13 subunits[46-48], which 
are guided by C/D Box snoRNAs to the appropriate 
base[49,50].
High 2’O-methylation levels in cancer
Tumor suppressor p53 and Fibrillarin seem to be 
linked[51]. Knockdown of p53 in cellular models of br­
east and colon cancer resulted in the overexpression 
of Fibrillarin at both the mRNA and protein levels. It is 
suggested that tumorigenesis associated to mutated 
p53 promotes an increase in the methylation status 
of rRNAs, which alters their ribozyme activity, thus 
affecting their translation fidelity and rate. Through 
the methylation of rRNA, Fibrillarin stimulates the 
translation of cancer-promoting proteins: (1) Insulin-
like growth factor 1 receptor (IGF1R), which plays 
a role in tumor progression, cell survival, and the 
response to chemotherapy (reviewed by Pollak et 
al[52]); (2) c-Myc, a pleiotropic pro-oncogene (reviewed 
by Dang et al [53]); (3) Fibroblast growth factor 1/2 
(FGF1/2), which is involved in epithelial-mesenchymal 
transition[54]; and (4) Vascular endothelial growth factor 
METTL3
METTL14
WTAP
ADAR1 p110
ADAR1 p150
ADAR2
TRDMT1
Nsun2
Box H/ACA
snoRNA
Dyskerin
m6A A I
C 5mC U ψ
ALKBH5
FTO Nucleus
Nucleus and cytosol
Nop58 
and 
Snu13
Fibrillarin
and Nol5a
Box C/D 
snoRNA
Figure 1  Ribonucleotide RNA modifications known to be of relevance in cancer and their enzymatic machineries. m6A: N6-methyladenosine; METTL3: 
Methyltransferase like 3; METTL14: Methyltransferase like 14; WTAP: Wilms’ tumor 1-associating protein; m6A erasers (ALKBH5: Alkylation repair homologue 
protein 5; FTO: Fat mass and obesity-associated protein); Inosine (I) writers [ADAR1 (p110 and p150) and ADAR2: Adenosine deaminase acting on RNA 1 and 2]; 
5-methylcytosine (5mC) (NSUN2: NOP2/Sun domain protein 2; TRDMT1: tRNA aspartic acid MTase 1); 2’O-methylation writers (Nol5a: Nucleolar Protein 5A; Nop58: 
Nucleolar protein 58; Snu13: Small Nuclear Ribonucleoprotein 13; SnoRNA: Small nucleolar RNA).
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A (VEGFA), which acts in tumoral angiogenesis[51,55]. 
Translation of these proteins relies on internal 
ribosome entry site (IRES) in the mRNA, which is a 
5’ cap-independent translation mechanism that may 
be used in specific conditions. The inhibition of rRNA 
methylation was shown to impair IRES translation in-
itiation by perturbing the association of the 40S and 60S 
subunits[56]. Therefore, it is conceivable that enhanced 
ribosomal methylation increases the translation of 
IRES-containing mRNAs. Nevertheless, clinical analysis 
shows that a high level of Fibrillarin in primary breast 
tumors is associated with poor survival, independent 
of other biological markers[51]. Elevated expression 
levels of Fibrillarin were previously reported in primary 
and metastatic prostate cancers and in squamous cell 
cervical carcinoma (Table 1)[57,58]. 
NOL5A gene was found to be overexpressed in Bu–
rkitt’s lymphoma-associated c-Myc mutants[59], and 
human NOP58 mRNA levels were found to be elevated 
in metastatic melanoma lesions[60].
Low 2’O-methylation levels in cancer 
Contrary to Fibrillarin’s indirect promotion of IRES-
driven translation, in MCF-7, a breast cancer cell line, 
Fibrillarin knockdown resulted in the accumulation of 
p53, possibly affecting the UTR of the p53 mRNA and 
increasing IRES-driven de novo synthesis[61]. These 
studies suggest a complex interplay between p53 and 
Fibrillarin, while IRES-dependent translation is not 
exclusively stimulated by increased rRNA methylation. 
Mixed 2’O-methylation in cancer
SnoRNA expression profiles were investigated in end-
ometrial, lung and prostate cancers, as well as in glioma 
and chronic lymphocytic leukemia. High­throughput scr­
eening of snoRNAs in cancerous versus normal tissues 
underlined their overexpression or underexpression as 
common molecular events in tumorigenesis, with the 
former being more pronounced than the latter[62-66]. 
Analysis of blood serum has shown the possibility of de­
tecting snoRNAs in breast cancer patient samples and 
the associated upregulation of a specific snoRNA, U6, in 
active disease[67]. Therefore, profiling snoRNAs with their 
respective RNA 2’O methylation modification signatures 
might be used as a noninvasive biomarker in the diagnosis 
and prognosis of cancer.
PSEUDOURIDINE IN CANCER RNA
The fifth base, known as pseudouridine (Ψ)[68], is one 
of the most abundant nucleotide modifications present 
in all three life domains[2]. After its initial detection 
in rRNA and tRNA, pseudouridine was detected in 
mRNA, lncRNA, and snRNAs, such as U2 snRNA and 
snoRNA[69,70]. Introducing Ψ in eukaryotic RNA can be 
mediated through guide RNA-dependent H/ACA BOX 
snoRNA pseudouridine synthases (PUSs) or guide RNA-
independent PUSs. A recent review by Penzo et al[71] 
reports on the functional roles of pseudouridines and 
related human pathologies.
Only low Ψ levels have been reported in cancer 
tissues/cells; thus, this chapter will contain only a 
section titled “low Ψ levels in cancer”. Surprisingly, 
elevated levels of circulating Ψ have been measured 
in the body fluids of cancer patients, but its role and 
origin are not well defined, so this finding will not be 
further discussed here.
Low Ψ levels in cancer
The highly conserved protein dyskerin is the human PUS 
that catalyzes the pseudouridylation of snoRNPs that 
assemble during the transcription of guide H/ACA RNA. 
Mutations in the Dkc1 gene coding for dyskerin can be 
found in the X-linked form of dyskeratosis congenita 
(DC). DC is a rare, inherited disorder that is characterized 
by mucocutaneous abnormalities and bone marrow 
failure. DC can be inherited as an X-linked recessive, 
autosomal dominant or autosomal recessive disease[72]. 
Although the absence of dyskerin, which results in 
the loss of pseudouridine in rRNA, was suggested as 
a primary cause of DC, a recent study assigned te-
lomerase dysfunction as the primary cause of DC[73]. 
Namely, mutations in H/ACA-resembling domains in the 
RNA component of telomerase RNP, which are required 
for telomerase accumulation, stability, 3’ end processing 
and function, are associated with an autosomal form of 
DC[74-76]. 
In patients with DC, a higher predisposition to cancer 
has been reported, although low mutational frequency 
in the DKC1 gene was shown in primary tumors[77]. 
This predisposition might be a synergistic outcome of 
impaired pseudouridylation. Most likely, the dysregulation 
of rRNA pseudouridylation precedes disease onset, as 
studies in hypomorphic Dkc1­mutant mice suggest. 
A specific defect of the internal ribosome entry site 
also occurs upon DKC1 loss, causing a specific defect 
in the translation of some IRES-containing mRNAs. 
Ribosomes that lack pseudouridine modifications show 
a direct impairment in binding to IRES elements[78]. 
Consequently, in hypomorphic DKC-1 mice, cap-de-
pendent translation of mRNA is not compromised, but 
translation of IRES-containing mRNAs, including the 
tumor suppressors p27 and p53, is perturbed[79-82], 
resulting in a higher incidence of cancer development 
in these mice. Thus, this impaired translation of tumor 
suppressor mRNA might also be a driver of cancer in DC 
patients. Moreover, recent identification of Ψ in mRNA[83] 
brings an additional level of complexity and regulation of 
the expression of target RNAs.
In hematological cancers, such as leukemias, ly-
mphoma and multiple myeloma, downregulation of 
specific subsets of dyskerin-associated H/ACA snoRNAs 
has been demonstrated[84-86] (Table 1). Thus, lower 
pseudouridylation levels are a widespread feature of 
cancer.
INOSINE IN CANCER RNA
Inosine is an RNA modification resulting from the hy-
drolytic deamination of adenosine catalyzed by adenosine 
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deaminase enzymes acting on double-stranded RNA 
(ADAR) or adenosine deaminase acting on transfer 
RNA (ADAT), which are families known to function in 
A-to-I RNA editing. Enzymes of the ADAR family are 
catalytically active ADAR1, ADAR2 and ADAR3, which still 
has an unknown function. 
ADARs introduce inosine in coding and non­co­
ding RNAs and have drastic impacts on the cellular 
transcriptome and translatome. The hypo­ or hyper­
editome has been associated with diverse types of 
cancer. The role of ADAT in cancer has not been reported.
High editing levels in cancer
Most frequently editing locations are long, partially 
complementary RNAs formed from inverted non­
coding repeats, such as Arthrobacter luteus (Alu) and 
long interspersed element (LINE) located in mRNA 
UTRs and introns. Two major studies have investigated 
RNA­editing patterns in tumors versus normal tissues. 
Each of the studies employed RNA-Seq datasets from 
The Cancer Genome Atlas (TCGA) project (https://
cancergenome.nih.gov/) and compared them to ref-
erence datasets of editing sites. High-confidence RNA 
editing sites are annotated in the Rigorously Annotated 
Database of A-to-I RNA Editing (RADAR, http://
rnaedit.com/), where one study focused on detecting 
Alu and non-Alu RNA editing events in 17 cancers, 
whereas the other study focused on Alu RNA editing 
events in 9 different cancers[87,88].
In general, elevated Alu editing activity in tumors 
compared to matched normal tissues was found in 
bladder urothelial carcinoma (BLCA), breast invasive 
carcinoma (BRCA), colon adenocarcinoma (COAD), 
head and neck squamous cell carcinoma (HNSC), lung 
adenocarcinoma (LUAD) and thyroid carcinoma (THCA). 
This hyperediting of Alu was attributed to ADAR1, whose 
expression levels matched in all these types of cancer, 
except COAD. Similarly, a study by Han et al[87] where 
more patient samples and non­Alu edited sequences 
were included, confirmed hyperediting in BLCA, BRCA, 
HNSC, LUAD, THCA compared to normal tissues. Again, 
increased editing levels correlated with the mRNA levels 
of ADAR1. 
Increased ADAR-1 levels were reported in non-small 
cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), 
esophageal cell carcinoma (ESCC), gastric (GC) and 
cervical cancer, suggesting that tight regulation of editing 
levels might have implications in cancer development 
and that ADAR1 might act as an oncogene[89-92] (Table 1 
and Figure 2). 
Recoding editing: In non-small cell lung cancer sa-
mples, ADAR1 gene amplification was shown to increase 
the editing of the DNA base excision repair glycosylase 
enzyme NEI-like protein 1 (NEIL1). Pre-mRNA editing 
of NEIL-1 causes a lysine to arginine (K242R) change 
in the lesion recognition loop of the protein. The edited 
NEIL1 protein removes thymine glycol from duplex DNA 
at a lower rate compared to the unedited form, while 
repair of the guanidinohydantoin lesion is enhanced 
by edited NEIL1[93]. In overexpression experiments, 
transfection of edited NEIL1 enhanced the growth 
of A459 cells in comparison with the transfection of 
unedited transcripts. Thus, increased recoding editing of 
NEIL1 as a proposed target of ADAR1 could contribute 
to the phenotype of lung cancer cells[94]. 
AZIN1 (encoding antizyme inhibitor 1) is edited by 
ADAR1, which has increased expression levels in HCC 
and was found to positively correlate with AZIN1 editing 
frequency. AZIN1 is an antizyme inhibitor whose activity 
is crucial in limiting cellular proliferation. Antizyme binds 
and induces the degradation of the growth­promoting 
proteins ornithine decarboxylase (ODC) and cyclin D1 
(CCND1)[95,96]. AZIN1 is homologous to ODC and has a 
greater binding affinity to antizyme compared to ODC. 
Binding of AZIN1 to antizyme prevents the degradation 
of ODC[97]. Thereby, AZIN1 acts as an oncogene by 
inhibiting the tumor-suppressor activities of antizyme[96]. 
AZIN1 expression was found to be substantially elevated 
in cancers of the prostate, brain, breast and liver, 
and gene expression data have identified alterations 
in the AZIN1-to-antizyme ratio in many human can-
cers, confirming its role in promoting growth[98-100]. In 
HCC, increased A-I editing of the AZIN1 transcript 
introduces serine­to­glycine substitution at residue 
367 in the protein. This recoding editing is associated 
with conformational changes and translocation from 
the nucleus to the cytoplasm and results in a higher­
binding affinity to antizyme and greater protein 
stability, thus promoting cell proliferation. AZIN1 editing 
increases during the progression from primary liver 
cancer and cirrhosis to advanced HCC with recurrence 
and metastasis, suggesting its use as a prognostic 
marker[101]. It is plausible that similar editing events 
occur in other types of cancer, as has been confirmed in 
esophageal squamous cell carcinoma (ESCC) and breast 
cancer[87,92,102]. Recently, tumorigenesis of NSCLC was 
also attributed to high levels of AZIN1 editing[103]. It has 
been reported that AZIN1 editing levels correlate with 
sensitivity to drug treatment in cancer cell lines. Cancer 
cells lines with increased levels of AZIN1 editing showed 
more sensitivity to some of the chemotherapies used in 
small cell lung cancer (SCLC): Paclitaxel, irinotecan, and 
topotecan[87].
Filamin B (FLNB) is an actin cross­linking protein 
and, together with filamin A, it forms homo- and he-
terodimers mediating orthogonal branching of actin 
filaments[104]. Filamin B is known to be a target for ed­
iting[105], and interestingly, one recoding editing event 
was shown to be increased in two types of cancer. In 
HCC, ADAR1 and ADAR2 were both reported to mediate 
FLNB transcript editing in codon 2269, resulting in the 
amino acid change Met→Val. Increased editing of FLNB 
compared to matched non­tumor liver tissues has been 
closely associated with HCC pathogenesis from normal 
to clinically verified HCC. In this study, ADAR1 levels 
were shown to be increased, while ADAR2 levels were 
decreased in HCC samples compared to non­tumor 
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liver tissues[90]. The same recoding editing was found in 
ESCC, where unlike HCC, only ADAR1 was responsible 
for this hyperediting. FLNB hyperediting correlated with 
ADAR1 levels in ESCC samples[92]. The functional role of 
FLNB editing is not known.
Ras homolog family member Q (RHOQ) belongs to a 
family of Rho GTPases that are known to be intracellular 
signaling molecules regulating the actin cytoskeleton 
and thereby cellular functions, such as cell polarity, 
migration, and vesicular trafficking. Rho GTPases are 
present as either an active GTP-bound form or an 
inactive GDP-bound form[106]. Activation of Rho GTPases 
is implicated in the development and progression of 
many types of human malignancies, including CRC[107]. 
RhoQ has been most extensively studied for its ce-
ntral role in insulin-stimulated GLUT4 transport in ad-
ipocytes[108]. Amino acid substitution of asparagine with 
serine (N136S) in the edited RhoQ was identified in 
colorectal cancer (CRC). The ADAR responsible has not 
been identified. This editing was suggested to change 
RhoQ protein–protein interactions and induce increased 
levels of RhoQ binding of GTP, causing actin cytoskeletal 
reorganization and increased invasion potential without 
affecting proliferation in CRC cell lines. Moreover, edited 
RHOQ was associated with recurrence of CRC when 
present in the tumor[109]. 
Protein tyrosine phosphatase non­receptor type 
6 (PTPN6) is a cytoplasmic protein expressed in hem-
atopoietic cell development, proliferation and the rec-
eptor­mediated mitogenic signaling pathway[110,111]. In 
bone marrow mononuclear cells (BMMCs) of patients 
with acute myeloid leukemia, a novel PTPN6 transcript 
retaining intron 3 has been identified. This transcript 
arises from an alternative splicing reaction where editing­
mediated deamination of A7866 in intron 3 erases 
this branch formation site, making it invisible to the sp-
licing machinery. The ADAR responsible has not been 
identified. It is suggested that this retention results in the 
translation of a nonfunctional protein where the intron 
3-encoded sequence is located in the N-terminal Src 
homology 2 (SH2) domain. PTPN6 binding with partner 
proteins, such as proto-oncogene receptor tyrosine 
kinase­c­Kit[112], and its self­inhibition of phosphatase 
activity occurs via its N terminal domain[113]. All this 
information suggests that its deregulation ultimately 
leads to uncontrolled hematopoietic growth and function. 
The tumor-specific editing seen in AML might correlate 
with the clinical course of the disease since low levels of 
intron­retaining transcripts in patient BMMCs at remission 
compared to those at diagnosis suggest that editing 
promotes tumorigenesis[114]. 
High miRNA editing levels in cancer: ADAR1 gene 
amplification in NSCLC demonstrated ADAR1 ove-
rexpression in patients with early-stage lung cancer, 
underlining its potential oncogenic role in this cancer. 
Increased levels of ADAR1 corresponded with edited 
miR-381 levels in NSCLC. Overexpression of edited 
miR-381 in NSCLC possibly contributes to stemness and 
chemoresistance[94]. 
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Low editing levels in cancer
Low levels of mRNA open reading frame editing 
in cancer: The same correlation but in the opposite 
direction was shown in hypoedited cancers, such as ki-
dney chromophobe (KICH) and kidney renal papillary 
cell carcinoma (KIRP), with ADAR1 mRNA paired editing 
levels. The ADAR2 levels checked in both studies 
showed a complex expression pattern but no matching 
editing levels (Table 1 and Figure 2)[87,88]. The role of 
ADAR1 in breast cancer is not fully understood. A re­
cent study reported high ADAR1 expression in half 
of the examined triple-negative-cancer patients[115]. 
Conversely, it has been proposed that ADAR1 prevents 
tumor progression by editing the transcript coding for 
the alpha­3 subunit of gamma­aminobutyric acid type A 
(Gabra3).
The chloride­permeable gamma­aminobutyric acid 
type A (GABAA) receptors are crucial mediators of fast 
inhibitory neurotransmission in the central nervous sy­
stem[116]. The Gabra3 transcript undergoes recoding 
editing of isoleucine to methionine (I/M) in the third 
transmembrane region. This substitution was found 
to affect GABAA surface presentation and its cellular 
trafficking[117]. In addition to being normally expressed 
in normal neuronal tissues, Gabra3 has been identified 
in breast cancer, where its high expression inversely 
correlates with breast cancer survival. ADAR1­edited 
Gabra3 was found in non-invasive breast cancer cell 
lines and was linked with the protein kinase B (Akt) 
pathway. A proposed mechanism for the non­invasive 
phenotype is that Gabra3 editing reduces its surface 
expression and indirectly prevents Akt activation, 
thereby preventing cell proliferation and invasiveness. 
Thus, the unedited form of Gabra3 in breast cancer is 
suggested to promote tumor progression, invasion and 
metastatic potential[118]. 
Lower ADAR2 levels are recognized in gastric ca-
ncer, glioblastoma, HCC and ESCC[91,119,120] (Figure 2). 
ADAR2 levels were found to correlate with changes in 
podocalyxin-like (PODXL) and GluR-B functions. The 
PODXL RNA editing event is an amino acid substitution 
from histidine (His) to arginine (Arg) at codon 241. 
This editing in the gastric cancer cell line MKN28 was 
shown to prevent increased growth rates and invasive 
capability compared to cells with the unedited form. 
Moreover, recoding editing of a single position located 
in the channel-pore-loop domain in GluR subunit B 
(GluR-B) (the Q/R-site) from Gln to Arg results in a ch-
annel that is impermeable to Ca2+[121]. Tight regulation 
of editing is essential for the adequate function of this 
channel. Hypoedited PODXL and GluR-B with altered 
functions are associated with gastric cancer and ma­
lignant glioblastoma, respectively. Consequently, a tum-
or-suppressor role has been attributed to ADAR2[91,119]. 
In ESCC, it has been reported that ADAR2 promotes 
apoptosis by editing and stabilizing insulin-like growth 
factor-binding protein 7 (IGFBP7) RNA. IGFBP7 is 
a secreted factor binding to and interfering with the 
activation of IGF1R. Through receptor occupation, 
IGFBP7 blocks downstream phosphatidylinositol 3-kin-
ase (PI3K)-AKT signaling, resulting in the inhibition of 
protein synthesis and cell apoptosis[122]. IGFBP7 was 
previously reported to be an apoptotic promoter in 
prostate cancer[123], colorectal cancer[124] and breast ca­
ncer[125]. The editing site in IGFBP7 is at position 284 
of the coding sequence, and codon 95 is changed from 
AAG (lysine) to AIG, which is read as AGG (arginine) 
(K95R). This editing was shown to protect IGFBP7 
against matriptase proteolysis in ESCC culture and 
xenografts, thus enabling the proapoptotic function of 
IGFBP7. ADAR2 is known to be downregulated in ESCC, 
and its upregulation induces apoptosis in ESCC cell lines 
in vitro, suggesting that IGFBP7 under editing may 
promote tumorigenesis in esophageal squamous cell 
carcinoma[120]. 
Low miRNA editing levels in cancer: ADAR2 res-
cue in glioblastoma cells was shown to inhibit cell 
proliferation and migration, confirming its possible 
tumor­suppressor role[126]. This anti­tumor effect mi­
ght be explained through the regulation of onco-miR-
NAs in glioblastoma. Three particularly investigated 
onco-miRNAs, miR-221, miR-222 and miR-21, are 
overexpressed in glioblastoma[127]. ADAR2 can edit 
miR-222/221 and miR-21 precursors and decrease the 
expression of the corresponding mature onco-miRNAs 
in the normal mouse brain and in different lines. 
Decreased levels of ADAR2 identified in glioblastoma 
probably push the balance of onco-miRNA/tumor-
suppressor miRNA towards increased expression of 
onco-miRNAs, such as miR-221, miR-222 and miR-21, 
thereby supporting tumor progression[128].
In the human brain, the miR-376 cluster encodes 
4 pri-miRs that give rise to 5 distinct mature miRNAs, 
which are subjected to specific A-to-I RNA editing on 
9 adenosines. In noninvasive U87 glioma cells, the 
expression of the unedited miR-376a* was shown to 
promote aggressive tumor migration and invasion 
of these cells both in vitro and in vivo. The editing 
reaction missing in the GBM cell lines generally occurs 
in the seed region of pri-miR-376a1 at the +9 site, 
ultimately giving rise to mature edited miR-376a*. The 
absence of this editing changes the specific targets 
of the miRNA. It has been identified that non edited 
miR-376a*, through its binding to 3’ UTR, has a novel 
target, RAP2A, which is a member of the RAS onc-
ogene family with an unknown function. However, the 
non edited miR-376a* targeting of RAP2A is unable to 
target the autocrine motility factor receptor (AMFR), 
resulting in its upregulation and possibly contributing 
to increased migration and invasiveness of glioma 
cells[129].
Melanoma is the most aggressive type of skin cancer. 
It has been reported that there is a significant decrease 
in ADAR1 expression in approximately 65% of metastatic 
melanoma specimens compared to melanocytes[130] 
(Table 1 and Figure 2). ADAR-1 transcripts were found 
to be targeted by miR-17 and miR-432, thus decreasing 
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ADAR1 expression. Both miR-17 and miR-432 were 
identified to be overexpressed in melanoma possibly 
due to the amplification of encoding genes[130]. However, 
studies suggest that ADAR1 insufficiencies contribute 
to the enhancement of proliferation of melanoma cells 
through editing the independent regulation of miRNA 
biogenesis. miRNA­455­5p was identified as a target 
of ADAR1 in low­metastatic melanoma cells but not in 
highly metastatic cell lines. ADAR1 was shown to edit 
pri-miR-455-5p at +2 and +17 positions. This editing 
probably results in the reduction of the processing of 
pri­miRNA by Dicer or Drosha by lowering the binding 
affinity. However, it is also possible that ADAR1 binds 
to Dicer since the amount of miR­455­5p bound to 
Dicer and Drosha was inversely correlated with ADAR1 
expression. ADAR1 was shown to form a complex 
with Dicer through protein­protein interactions[131]. In 
this study, the authors gave a model of RNA editing in 
the context of melanoma progression and metastasis, 
where cAMP responses element binding (CREB) dow­
nregulates ADAR1 and gives rise to non­edited miR­
455-5p. Expression of miR-455-5p suppresses the 
tumor suppressor gene cytoplasmic polyadenylation 
element-binding protein 1 (CPEB1), resulting in growth 
promotion and metastasis in melanoma cells[132]. 
M5C IN CANCER RNA
Cytosine base methylation - m5C has been identified in 
rRNA, tRNA and recently in mRNAs and is particularly 
enriched in untranslated regions and near Argonaute­
binding regions[133]. The enzymes responsible for the 
introduction of m5C are members of the DNA meth­
yltransferase homolog (Dnmt2) and the NOP2/Sun 
(NSun 2 and 4) RNA methyltransferase family[134-136]. 
The role of these enzymes in the methylating activities 
of tumorigenesis is currently unknown. However, in 
circulating tumor cells from lung cancer patients, inc-
reased RNA m5C levels were shown compared to those 
in whole blood cells[137]. Further investigation of the role 
of m5C in cancer is required.
CONCLUSION
Tight regulation of the writing, reading and eventual 
erasing of RNA modifications is essential for RNA me­
tabolism. Misbalanced expression of the enzymes re-
sponsible for introducing, and in some cases removing, 
these modifications are considered a possible signature 
for specific types of cancer (Table 1). Considering 
the broad effect of RNA modifications on tumor cell 
biology, future methylome, pseudome and editome 
studies will shed light on those relatively unexplored ep-
itranscriptomic mechanisms in tumors. Those studies will 
pave the way for the development of anti­cancer drugs 
that could act by steering RNA modifications.
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